These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29245952)

  • 1. The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.
    Bougherara H; Némati F; Nicolas A; Massonnet G; Pugnière M; Ngô C; Le Frère-Belda MA; Leary A; Alexandre J; Meseure D; Barret JM; Navarro-Teulon I; Pèlegrin A; Roman-Roman S; Prost JF; Donnadieu E; Decaudin D
    Oncotarget; 2017 Nov; 8(59):99950-99965. PubMed ID: 29245952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
    Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
    Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR.
    Gill SE; Zhang Q; Keeney GL; Cliby WA; Weroha SJ
    Oncotarget; 2017 Oct; 8(49):85214-85223. PubMed ID: 29156714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer.
    Barret JM; Nicolas A; Jarry A; Dubreuil O; Meseure D; Passat T; Perrial E; Deleine C; Champenois G; Gaillard S; Duchalais E; Ray-Coquard I; Lahmar M; Dumontet C; Bennouna J; Bossard C; Roman-Roman S; Prost JF
    Biology (Basel); 2021 Apr; 10(4):. PubMed ID: 33917111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
    Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
    MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.
    Prat M; Salon M; Allain T; Dubreuil O; Noël G; Preisser L; Jean B; Cassard L; Lemée F; Tabah-Fish I; Pipy B; Jeannin P; Prost JF; Barret JM; Coste A
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria.
    Kim SM; Kim YO; Lee MK; Chung YJ; Jeung IC; Kim MR; Kim JH
    Oncol Lett; 2019 Jan; 17(1):532-538. PubMed ID: 30655798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth.
    Baarends WM; Uilenbroek JT; Kramer P; Hoogerbrugge JW; van Leeuwen EC; Themmen AP; Grootegoed JA
    Endocrinology; 1995 Nov; 136(11):4951-62. PubMed ID: 7588229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat.
    Baarends WM; Hoogerbrugge JW; Post M; Visser JA; De Rooij DG; Parvinen M; Themmen AP; Grootegoed JA
    Endocrinology; 1995 Dec; 136(12):5614-22. PubMed ID: 7588316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Müllerian inhibiting substance inhibits an ovarian cancer cell line via β-catenin interacting protein deregulation of the Wnt signal pathway.
    Park SH; Chung YJ; Song JY; Kim SI; Pépin D; MacLaughlin DT; Donahoe PK; Kim JH
    Int J Oncol; 2017 Mar; 50(3):1022-1028. PubMed ID: 28197641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of anti-Müllerian hormone (amh) and anti-Müllerian hormone receptor type II (amhrII) in the teleost medaka.
    Klüver N; Pfennig F; Pala I; Storch K; Schlieder M; Froschauer A; Gutzeit HO; Schartl M
    Dev Dyn; 2007 Jan; 236(1):271-81. PubMed ID: 17075875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Müllerian hormone gene polymorphism is associated with androgen levels in Chinese polycystic ovary syndrome patients with insulin resistance.
    Zheng MX; Li Y; Hu R; Wang FM; Zhang XM; Guan B
    J Assist Reprod Genet; 2016 Feb; 33(2):199-205. PubMed ID: 26732661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Müllerian hormone type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries.
    Rice S; Ojha K; Whitehead S; Mason H
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1034-40. PubMed ID: 17179193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Müllerian hormone is associated with extrauterine involvement and stage of disease in patients with endometrial cancer.
    Dogan NU; Kerimoglu OS; Karabagli P; Pekin A; Yilmaz SA; Incesu F; Celik C
    J Obstet Gynaecol; 2015 Feb; 35(2):178-82. PubMed ID: 25111828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile(49)Ser) and Anti-Müllerian hormone type II receptor (AMHRII -482 A>G) as genetic markers in assisted reproduction technology.
    Karagiorga I; Partsinevelos GA; Mavrogianni D; Anagnostou E; Zervomanolakis I; Kallianidis K; Drakakis P; Loutradis D
    J Assist Reprod Genet; 2015 Mar; 32(3):357-67. PubMed ID: 25542251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placenta expresses anti-Müllerian hormone and its receptor: Sex-related difference in fetal membranes.
    Novembri R; Funghi L; Voltolini C; Belmonte G; Vannuccini S; Torricelli M; Petraglia F
    Placenta; 2015 Jul; 36(7):731-7. PubMed ID: 25972076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II.
    Mazumder S; Swank V; Komar AA; Johnson JM; Tuohy VK
    Oncotarget; 2020 May; 11(20):1894-1910. PubMed ID: 32499873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
    Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
    Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of antimüllerian hormone and its receptor in endometriosis.
    Carrarelli P; Rocha AL; Belmonte G; Zupi E; Abrão MS; Arcuri F; Piomboni P; Petraglia F
    Fertil Steril; 2014 May; 101(5):1353-8. PubMed ID: 24613539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.